We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$174M
AUM Growth
+$18.3M
Cap. Flow
-$2.25M
Cap. Flow %
-1.29%
Top 10 Hldgs %
90.88%
Holding
46
New
4
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
AXDX
Accelerate Diagnostics
AXDX
+$1.61M
2
KURA icon
Kura Oncology
KURA
+$829K
3
NBIX icon
Neurocrine Biosciences
NBIX
+$686K
4
WMGI
Wright Medical Group Inc
WMGI
+$650K
5
CORT icon
Corcept Therapeutics
CORT
+$361K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$2.31M
2
SWN
Southwestern Energy Company
SWN
+$1.22M
3
CLR
CONTINENTAL RESOURCES INC.
CLR
+$947K
4
GILD icon
Gilead Sciences
GILD
+$936K
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$626K

Sector Composition

Rank Sector Weight
1 Healthcare 93.93%
2 Energy 2.09%
3 Consumer Staples 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$162B
$387K 0.22%
3,820
-9,000
-70% -$936K
PXD
27
DELISTED
Pioneer Natural Resource Co.
PXD
$376K 0.22%
3,000
– –
SIEN
28
DELISTED
Sientra, Inc.
SIEN
$375K 0.22%
6,330
-500
-7% -$26K
CTRA
29
DELISTED
Coterra Energy
CTRA
$371K 0.21%
21,000
– –
TSRO
30
DELISTED
TESARO, Inc.
TSRO
$364K 0.21%
+6,950
New +$332K
ADXS
31
DELISTED
Advaxis Inc
ADXS
$358K 0.21%
2,373
– –
BIIB icon
32
Biogen
BIIB
$29.6B
$306K 0.18%
1,000
– –
CELGZ
33
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$286K 0.16%
238,214
– –
TTHI
34
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$280K 0.16%
145,746
– –
MACK
35
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$237K 0.14%
3,813
-1,563
-29% -$110K
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.16B
$221K 0.13%
3,400
– –
RPTP
37
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$208K 0.12%
40,000
-14,000
-26% -$81.2K
ROKA
38
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$187K 0.11%
15,231
– –
XNCR icon
39
Xencor
XNCR
$1.45B
$180K 0.1%
12,300
– –
CHRS icon
40
Coherus Oncology
CHRS
$221M
$172K 0.1%
7,500
– –
PBYI icon
41
Puma Biotechnology
PBYI
$408M
– –
-2,150
Closed -$162K
SWN
42
DELISTED
Southwestern Energy Company
SWN
– –
-96,483
Closed -$1.22M
CLR
43
DELISTED
CONTINENTAL RESOURCES INC.
CLR
– –
-32,674
Closed -$947K
AEGR
44
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-46,000
Closed -$626K
TRNX
45
DELISTED
TORNIER N V SHARES (NLD)
TRNX
– –
-30,000
Closed -$612K
PQUE
46
DELISTED
PETROQUEST ENERGY INC (DE)
PQUE
– –
-122,050
Closed -$143K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Birchview Capital held 46 positions worth $174M, up 12% from $155M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q4 2015 filing shows 4 new, 6 increased, 8 reduced and 6 closed positions. Its largest new stake was Kura Oncology: 105,285 shares worth $884K. The largest sale was Celgene Corp, an estimated $2.31M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2015 buy was Kura Oncology: 105,285 shares worth $884K.
  • Birchview Capital added most to Accelerate Diagnostics in Q4 2015, an estimated $1.61M increase.
  • Birchview Capital's biggest Q4 2015 reduction was Celgene Corp, cutting an estimated $2.31M.
  • Birchview Capital fully exited Southwestern Energy Company in Q4 2015, selling an estimated $1.22M.
  • Birchview Capital's ten largest holdings make up 91% of its $174M portfolio in Q4 2015.
  • Birchview Capital opened 4 new positions and closed 6 in Q4 2015.
  • Birchview Capital's portfolio value rose 12% quarter-over-quarter to $174M.

Based on Birchview Capital's 13F filing for Q4 2015, filed 8 Feb 2016.